Lumida
/SLNO
⌘K
Soleno Therapeutics Inc

Soleno Therapeutics Inc

SLNO
$53.01USD↑+0.04%+0.02 today

MARKET CAP

2.8B

P/E (TTM)

29.3x

FWD P/E

—

DAY RANGE

$53 – $53

52W RANGE

$29
$90

AI Summary

Stalk
StalkMedium

SLNO remains in an early Stage 1 consolidation with its 9/20 EMAs repaired and supporting price. Medium-term directional asymmetry is bullish, driven by multiple continuation patterns signaling demand dominance. However, price is extended and overbought with exhaustion visible in RSI and options. Execution should be deferred until a shallow pullback into the rising EMA cluster emerges to confirm support before engaging.

  • ↑Q4 net revenue $91.7M (+40% sequential) and FY25 sales of $190.4M
  • ↑1,250 patient start forms (~12.5% addressable US market) with 859 active patients
  • ↓Lag from patient start forms to active dosing may pressure quarterly revenue
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a biotechnology company focused on developing treatments for rare diseases, primarily targeting Prader-Willi syndrome (PWS) through its flagship product, BICAT XR. This product addresses hyperphagia, a condition caused by PWS, and positions Soleno within the emerging rare disease treatment space, supported by strategic initiatives in commercialization and regulatory approvals.

Bull says

  • ↑Q4 net revenue $91.7M (+40% sequential) and FY25 sales of $190.4M
  • ↑1,250 patient start forms (~12.5% addressable US market) with 859 active patients
  • ↑Operating cash flow $48.7M in Q4; $500M+ cash and marketable securities
  • ↑Positive net income $20.9M in FY25 vs $175.9M loss in FY24
  • ↑EU approval decision expected mid-2026, opening a new growth market
  • ↑First-mover for PWS hyperphagia with strong patient engagement and prescriber network

Bear says

  • ↓Lag from patient start forms to active dosing may pressure quarterly revenue
  • ↓Cumulative 12% discontinuation rate could limit overall market capture
  • ↓Delays from EMA approval may push back EU launch timing
  • ↓Pricing pressures loom if competitors introduce alternative PWS therapies
  • ↓Rival products from Rhythm and others threaten to erode share
  • ↓Adoption uncertainties and conversion challenges temper near-term growth outlook

Investment themes with SLNO

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 07-17-2026neutral

Transcript signals

Bull points

  • This approval is the culmination of many years of tireless work by the entire Celeno team, without whom none of this would have been possible.
  • We are very pleased to offer VICAD XR for individuals and families who have been waiting for a treatment option for the symptoms related to this devastating disease since it was first recognized in 1956.
  • Following approval and reflecting our progress in establishing our commercial readiness, we were able to move very quickly to launch.

Bear points

  • we have looked through our supply chain, and I would suggest that really we don't see any significant impact with the way the tariffs are currently being phrased. We do most of our manufacturing in the U.S., so we feel that it's not something that's going to impact us to any great extent.
  • Therefore, as is typical in these types of launches, we expect revenues to start off modestly.
  • the unmet need here is pretty significant.
Read full transcript analysis ›